- Home
- ONMD vs BCAB Comparison
ONMD vs BCAB Comparison
Compare ONMD & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONMD
- BCAB
- Stock Information
- Founded
- ONMD 2006
- BCAB 2007
- Country
- ONMD United States
- BCAB United States
- Employees
- ONMD N/A
- BCAB 61
- Industry
- ONMD
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- ONMD
- BCAB Health Care
- Exchange
- ONMD Nasdaq
- BCAB Nasdaq
- Market Cap
- ONMD 22.2M
- BCAB 31.5M
- IPO Year
- ONMD N/A
- BCAB 2020
- Fundamental
- Price
- ONMD $0.85
- BCAB $0.61
- Analyst Decision
- ONMD
- BCAB Hold
- Analyst Count
- ONMD 0
- BCAB 3
- Target Price
- ONMD N/A
- BCAB $1.00
- AVG Volume (30 Days)
- ONMD 19.0M
- BCAB 745.7K
- Earning Date
- ONMD 08-13-2025
- BCAB 11-06-2025
- Dividend Yield
- ONMD N/A
- BCAB N/A
- EPS Growth
- ONMD N/A
- BCAB N/A
- EPS
- ONMD N/A
- BCAB N/A
- Revenue
- ONMD $459,000.00
- BCAB $11,000,000.00
- Revenue This Year
- ONMD N/A
- BCAB N/A
- Revenue Next Year
- ONMD N/A
- BCAB N/A
- P/E Ratio
- ONMD N/A
- BCAB N/A
- Revenue Growth
- ONMD N/A
- BCAB N/A
- 52 Week Low
- ONMD $0.30
- BCAB $0.24
- 52 Week High
- ONMD $1.56
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- ONMD 58.80
- BCAB 77.82
- Support Level
- ONMD $0.82
- BCAB $0.44
- Resistance Level
- ONMD $0.92
- BCAB $0.46
- Average True Range (ATR)
- ONMD 0.10
- BCAB 0.04
- MACD
- ONMD 0.00
- BCAB 0.02
- Stochastic Oscillator
- ONMD 75.81
- BCAB 92.43
About ONMD OneMedNet Corp
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its innovative solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. OneMedNet's innovative technology proved the commercial and regulatory viability of imaging Real World Data (as defined below), an emerging market, and provides regulatory-grade image-centric iRWDTM that exactly matches OneMedNet's life science partners' case selection protocols and paves the way for Real World Evidence.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.